16 April, 2019 / No comment
- April 23rd, 2019. VaxNewMo’s patent US15/533,733 issued and granted by the United States Patent Office.
- April 16th, 2019. Check out our latest review article on glycoengineering coli for bioconjugate vaccine, therapeutic and diagnostic production: https://academic.oup.com/glycob/advance-article/doi/10.1093/glycob/cwz031/5467302
- March 11th, 2019. VaxNewMo awarded its third Phase I SBIR/STTR grant from the NIAID to develop bioconjugate vaccines against Group B
- February 28th, 2019. VaxNewMo highlighted by the St. Louis Business Journal for its success in with multiple SBIR/STTR grant awards and vaccine platform – https://www.bizjournals.com/stlouis/news/2019/02/28/how-one-st-louis-biotech-startup-is-proving-its.html
- February 21st, 2019. VaxNewMo publishes its platform technology manuscript in Nature Communications – https://www.nature.com/articles/s41467-019-08869-9
- January 17th, 2019. Dr. Harding presents VaxNewMo’s bioconjugation platform during the Peptalk: The Protein Science Week in San Diego, CA.
- June 13th, 2018. Dr. Harding presents latest VaxNewMo’s pneumococcal bioconjugate data to the FASEB Microbial Glycobiology Conference in Scottsdale, Arizona.
- January 13th, 2018. Dr. Harding presents VaxNewMo’s latest achievements at the Peptalk 2018: The Protein Science Week in San Diego, CA.
- December 20th, 2017. VaxNewMo awarded its second Phase I SBIR/STTR grant to develop a multivalent bioconjugate vaccine against Klebsiella pneumoniae.
- February 21st, 2017. VaxNewMo awarded its first Phase I SBIR/STTR grant to develop the most broadly encompassing pneumococcal bioconjugate vaccine.